In vitro activity of novel in silico-developed antimicrobial peptides against a panel of bacterial pathogens

Journal of Peptide Science

Volumn 19, Issue 9, 2013, Pages 554-565

  Romani, A A ^a   Baroni, M C ^a   Taddei, S ^a   Ghidini, F ^a   Sansoni, P ^a   Cavirani, S ^a   Cabassi, C S ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Antimicrobial activity; Antimicrobial peptides; Combined therapy; Cytoplasmic membrane permeabilization; Hemolysis

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMP 126; AMP 2041; AMP 72; CALCIUM ION; COLISTIN; DIVALENT CATION; EDETIC ACID; MAGNESIUM ION; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CELL COUNT; CIRCULAR DICHROISM; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DRUG DESIGN; DRUG PENETRATION; DRUG SYNTHESIS; ENDOTHELIUM CELL; EPITHELIUM CELL; ESCHERICHIA COLI; FEMALE; FETUS; FIBROBLAST; FOURIER TRANSFORMATION; HEMOLYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM BACTERICIDAL CONCENTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; RECEIVER OPERATING CHARACTERISTIC; SALMONELLA ENTERITIDIS; SEQUENCE ALIGNMENT; SHEEP ERYTHROCYTE; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS AGALACTIAE;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; OVIS ARIES; POSIBACTERIA;

ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL PEPTIDES; COMBINED THERAPY; CYTOPLASMIC MEMBRANE PERMEABILIZATION; HEMOLYSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL LINE; CELL MEMBRANE PERMEABILITY; CHELATING AGENTS; COMPUTER SIMULATION; DRUG SYNERGISM; EDETIC ACID; ERYTHROCYTES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; NEURAL NETWORKS (COMPUTER); ROC CURVE; SHEEP, DOMESTIC;

EID: 84882261077     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2532     Document Type: Article

References (40)

1. Pile JC. Antimicrobial stewardship: optimizing antibiotic use in an era of increasing resistance and rising costs. J. Hosp. Med. 2011; 6: S1-S3.
2. Overbye KM, Barrett JF. Antibiotics: where did we go wrong? Drug Discov. Today 2005; 10: 45-52.
3. Projan SJ, Shlaes DM. Antibacterial drug discovery: is it all downhill from here? Clin. Microbiol. Infect. 2004; 10: 18-22.
4. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, Icket C, Kalenic S, Horvatic J, Seifert H, Kaasch AJ, Paniara O, Argyropoulou A, Bompola M, Smyth E, Skally M, Raglio A, Dumpis U, Kelmere AM, Borg M, Xuereb D, Ghita MC, Noble M, Kolman J, Grabljevec S, Turner D, Lansbury L, Grundmann H. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob. Agents Chemother. 2011; 55: 1598-1605.
5. ECDC/EMEA Joint Working Group. ECDC/ EMEA joint technical report: the bacterial challenge: time to react. Stockholm: European Centre for Disease Prevention and Control, 2009. DOI: 10.2900/2518.
6. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect. 2007; 13: 560-578.
7. Oyston PC, Fox MA, Richards SJ, Clark GC. Novel peptide therapeutics for treatment of infections. J. Med. Microbiol. 2009; 58: 977-987.
8. Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 2001; 1: 156-164.
9. Hwang PM, Vogel HJ. Structure-function relationships of antimicrobial peptides. Biochem. Cell Biol. 1998; 76: 235-246.
10. Cudic M, Otvos L, Jr. Intracellular targets of antibacterial peptides. Curr. Drug Targets 2002; 3: 101-106.
11. Zasloff M. Antimicrobial peptides in health and disease. N. Engl. J. Med. 2002; 347: 1199-1200.
12. Makoto M, Takuji N. Mersenne twister: a 623-dimensionally equidistributed uniform pseudo-random number generator. ACM Trans. Model. Comput. Simul. 1998; 8: 3-30.
13. Erb RJ. Introduction to backpropagation neural network computation. Pharm. Res. 1993; 10: 165-170.
14. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 2002; 30: 3059-3066.
15. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993; 234: 779-815.
16. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. J. Comput. Chem. 2005; 26: 1701-1718.
17. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 1996; 8: 477-486.
18. Shindyalov IN, Bourne PE. Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Eng. 1998; 11: 739-747.
19. Unneberg P, Merelo JJ, Chacon P, Moran F. SOMCD: method for evaluating protein secondary structure from UV circular dichroism spectra. Proteins 2001; 42: 460-470.
20. CSLI. Performance Standards for Antimicrobial Disks and Dilution Susceptibility Test Form Isolated from Animals. CLSI: Wayne, Pennsylvania, USA, 2008.
21. Tossi A, Tarantino C, Romeo D. Design of synthetic antimicrobial peptides based on sequence analogy and amphipathicity. Eur. J. Biochem. 1997; 250: 549-558.
22. Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer cultures. Anal. Biochem. 1986; 159: 109-113.
23. Bonapace CR, Bosso JA, Friedrich LV, White RL. Comparison of methods of interpretation of checkerboard synergy testing. Diagn. Microbiol. Infect. Dis. 2002; 44: 363-366.
24. http://www.bbcm.univ.trieste.it/~tossi/search.htm [last update: 03/10/2003]
25. Wang G, Li X, Wang Z. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res. 2009; 37: D933-D937.
26. Thomas S, Karnik S, Barai RS, Jayaraman VK, Idicula-Thomas S. CAMP: a useful resource for research on antimicrobial peptides. Nucleic Acids Res. 2010; 38: D774-780.
27. Seebah S, Suresh A, Zhuo S, Choong YH, Chua H, Chuon D, Beuerman R, Verma C. Defensins knowledgebase: a manually curated database and information source focused on the defensins family of antimicrobial peptides. Nucleic Acids Res. 2007; 35: D265-D268.
28. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 2003; 55: 27-55.
29. Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era? Arch. Med. Res. 2005; 36: 697-705.
30. Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: premises and promises. Int. J. Antimicrob. Agents 2004; 24: 536-547.
31. De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol. Lett. 2005; 27: 1337-1347.
32. McManus AM, Otvos L, Jr., Hoffmann R, Craik DJ. Conformational studies by NMR of the antimicrobial peptide, drosocin, and its non-glycosylated derivative: effects of glycosylation on solution conformation. Biochemistry 1999; 38: 705-714.
33. Oren Z, Shai Y. Mode of action of linear amphipathic α-helical antimicrobial peptides. Biopolymers 1998; 47: 451-463.
34. Skerlavaj B, Romeo D, Gennaro R. Rapid membrane permeabilization and inhibition of vital functions of Gram-negative bacteria by bactenecins. Infect. Immun. 1990; 58: 3724-3730.
35. Matsuzaki K, Sugishita K, Harada M, Fujii N, Miyajima K. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. Biochim. Biophys. Acta 1997; 1327: 119-130.
36. Dathe M, Schumann M, Wieprecht T, Winkler A, Beyermann M, Krause E, Matsuzaki K, Murase O, Bienert M. Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 1996; 35: 12612-12622.
37. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 1992; 56: 395-411.
38. Lecomte S, Baron MH, Chenon MT, Coupry C, Moreau NJ. Effect of magnesium complexation by fluoroquinolones on their antibacterial properties. Antimicrob. Agents Chemother. 1994; 38: 2810-2816.
39. Mao W, Warren MS, Lee A, Mistry A, Lomovskaya O. MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2001; 45: 2001-2007.
40. Boman HG. Antibacterial peptides: basic facts and emerging concepts. J. Int. Med. 2003; 254: 197-215.